A Phase 1, Single Ascending Dose and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002 in Patients With Indolent Systemic Mastocytosis

Trial Profile

A Phase 1, Single Ascending Dose and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002 in Patients With Indolent Systemic Mastocytosis

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Jun 2018

At a glance

  • Drugs AK 002 (Primary)
  • Indications Systemic mastocytosis
  • Focus Adverse reactions
  • Sponsors Allakos
  • Most Recent Events

    • 06 Jun 2018 Planned primary completion date changed from 1 Sep 2018 to 1 Dec 2018.
    • 06 Jun 2018 Status changed from recruiting to active, no longer recruiting.
    • 18 Dec 2017 Planned End Date changed from 1 Aug 2017 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top